Top

Published in:

01-11-2009 | Case Report

Pancytopenia Associated with Levetiracetam Treatment

Authors: Dr Massimo Gallerani, Elisa Mari, Benedetta Boari, Rossella Carletti, Anna Marra, Michele Cavallo

Published in: Clinical Drug Investigation | Issue 11/2009

Abstract

Levetiracetam is a pyrrolidine derivate that is approved for the treatment of seizures. It has a favourable pharmacokinetic profile, no clearly established pharmacological interactions, good tolerability and offers the possibility of rapid treatment.

We describe a case of pancytopenia and multiple infections observed in the context of levetiracetam treatment. A 65-year-old woman who underwent surgical removal of a meningioma developed progressive pancytopenia complicated by pneumonia and multiple liver abscesses after starting levetiracetam therapy. Bone marrow aspiration and biopsy confirmed the diagnosis. A gradual spontaneous recovery of normal haematopoiesis followed discontinuation of levetiracetam.

Sirsi D, Safdieh JE. The safety of levetiracetam. Expert Opin Drug Saf 2007; 6: 241–50PubMedCrossRef

De Smedt T, Raedt R, Vonck K, et al. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev 2007; 13: 57–78PubMedCrossRef

Keppra®, product information 2009 [online]. Available from URL: http://www.keppra.com/pc/home/default.asp [Accessed 2009 Jul 7]

Bauer J, Ben-Menachem E, Kramer G, et al. Levetiracetam: a long-term follow-up study of efficacy and safety. Acta Neurol Scand 2006; 114: 169–76PubMedCrossRef

Glauser TA, Pellock JM, Bebin EM, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 2002; 43: 518–24PubMedCrossRef

Boon P, Hulhoven R, Offner F. Levetiracetam and bleeding disorders. Acta Neurol Belg 2007; 107: 97–102PubMed

Hartmann H, Schumacher U, Seeck M. Verschlechterung einer Immunthrombopenie unter Monotherapie mit Levetiracetam. Aktuel Neurol 2002; 29: 467–8CrossRef

Kimland E, Höjeberg B, von Euler M. Levetiracetam-induced thrombocytopenia. Epilepsia 2004; 45: 877–8PubMedCrossRef

Meschede A, Runge U, Sabolek M. Thrombocytopenia during levetiracetam therapy. Epilepsy Res 2008; 80: 91–2PubMedCrossRef

10.

Elouni B, Ben Salem C, Biour M. Levetiracetam-induced pancytopenia [letter]. Ann Pharmacother 2009; 43: 985PubMedCrossRef

11.

Rete Nazionale di Farmacovigilanza, Italia [online]. Available from URL: https://nsis.sanita.it/ACCN/accessportalnsis/ [Accessed 2009 Apr 27]

12.

Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45PubMedCrossRef

13.

Irastorza Eguskiza LJ. Leukopenia as side effect of paroxetine. Actas Esp Psiquiatr 2004; 32: 327–8PubMed

14.

Moselhy HF, Conlon W. Neutropenia associated with paroxetine [letter]. IR J Psychol Med 1999; 16: 75

Title: Pancytopenia Associated with Levetiracetam Treatment
Authors: Dr Massimo Gallerani
Elisa Mari
Benedetta Boari
Rossella Carletti
Anna Marra
Michele Cavallo
Publication date: 01-11-2009
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 11/2009
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.2165/11319450-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pancytopenia Associated with Levetiracetam Treatment

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2009

Perioperative Use of Nonsteroidal Anti-Inflammatory Drugs

Safety/Tolerability and Efficacy of Rivastigmine in Taiwanese Patients with Alzheimer’s Disease

Effects of Benidipine, a Long-Acting T-Type Calcium Channel Blocker, on Home Blood Pressure and Renal Function in Patients with Essential Hypertension

Pharmacokinetics and Antihypertensive Effects of Candesartan Cilexetil in Patients Undergoing Haemodialysis

Clinical and Economic Comparison of Frovatriptan Versus other Oral Triptans in the Treatment of Acute Migraine in the Real-World Setting

Comparison of the Pharmacokinetics of Apricitabine in the Presence and Absence of Ritonavir-Boosted Tipranavir